- Home
- FENC vs SABA Comparison
FENC vs SABA Comparison
Compare FENC & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$9.04
Company Overview
Basic Information| Metric | FENC | SABA |
|---|---|---|
| Founded | 1996 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.8M | 225.6M |
| IPO Year | 2010 | 1994 |
Fundamental Metrics
Financial Performance| Metric | FENC | SABA |
|---|---|---|
| Price | $9.04 | $8.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 263.7K | 39.6K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.91% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $44,642,000.00 | N/A |
| Revenue This Year | $65.12 | N/A |
| Revenue Next Year | $41.08 | N/A |
| P/E Ratio | $906.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.65 | $7.96 |
| 52 Week High | $10.45 | $9.46 |
Technical Indicators
Market Signals| Indicator | FENC | SABA |
|---|---|---|
| Relative Strength Index (RSI) | 54.46 | 37.67 |
| Support Level | $8.25 | $7.97 |
| Resistance Level | $9.15 | $8.24 |
| Average True Range (ATR) | 0.49 | 0.12 |
| MACD | -0.12 | -0.02 |
| Stochastic Oscillator | 36.21 | 5.88 |
Price Performance
Historical Comparison FENC
SABA
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.